Touro Scholar
NYMC Faculty Publications

Faculty

8-9-2016

Schizophrenia Relapse, Patient Considerations, and Potential Role
of Lurasidone
Leslie L. Citrome
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Psychiatry and Psychology Commons

Recommended Citation
Citrome, L. (2016). Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient
Preference and Adherence, 10, 1529-1537. doi:10.2147/PPA.S45401

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information,
please contact touro.scholar@touro.edu.

Patient Preference and Adherence

Dovepress
open access to scientific and medical research

Review

Patient Preference and Adherence downloaded from https://www.dovepress.com/ by 104.246.5.88 on 06-Dec-2016
For personal use only.

Open Access Full Text Article

Schizophrenia relapse, patient considerations,
and potential role of lurasidone
This article was published in the following Dove Press journal:
Patient Preference and Adherence
9 August 2016
Number of times this article has been viewed

Leslie Citrome
Department of Psychiatry and
Behavioral Sciences, New York
Medical College, Valhalla, NY, USA

Introduction

Correspondence: Leslie Citrome
11 Medical Park Drive, Suite 106,
Pomona, NY 10970, USA
Tel +1 845 362 2081
Fax +1 845 362 8745
Email citrome@cnsconsultant.com

Optimal management of schizophrenia requires adequate symptom control and
avoidance of exacerbation or relapse. Unfortunately, relapse is common, with an
estimate of 80% of patients experiencing a relapse in their first 5 years of treatment.1
Delaying time to relapse is a primary goal when using antipsychotic medication, and
may mitigate against further decline.2 Lifelong use of antipsychotic medication is thus
required.3 Unfortunately, antipsychotic medications are associated with a myriad of
adverse effects.4,5 Demonstrated differences in tolerability profiles among the different
choices of antipsychotics6 make it possible to attempt to match up an individual patient
to the best choice for such patient based on past history of tolerability, comorbidities,
and personal preferences.7,8
Lurasidone is a second-generation (atypical) antipsychotic agent that has demonstrated efficacy in the treatment of patients with schizophrenia, and it is approved as
such in the United States, Canada, the European Union, Switzerland, and Australia;
it is also approved in the United States and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate.9 Lurasidone’s pharmacodynamic profile is
distinguished by its relatively high affinity for serotonin 5-HT7 receptors and its
partial agonist activity at 5-HT1A receptors, together with being a full antagonist at
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Abstract: When treating persons with schizophrenia, delaying time to relapse is a main goal.
Antipsychotic medication has been the primary treatment approach, and there are a variety of
different choices available. Lurasidone is a second-generation (atypical) antipsychotic agent
that is approved for the treatment of schizophrenia and bipolar depression. Three long-term
studies of lurasidone have examined time to relapse in persons with schizophrenia, including a
classic placebo-controlled randomized withdrawal study and two 12-month active comparator
studies (vs risperidone and vs quetiapine extended-release). Lurasidone 40–80 mg/d evidenced
superiority over placebo (number needed to treat [NNT] vs placebo for relapse, 9). Lurasidone
40–160 mg/d was noninferior to quetiapine extended-release 200–800 mg/d on the outcome
of relapse, and was superior on the outcome of avoidance of hospitalization (NNT 8) and the
outcome of remission (NNT 7). Lurasidone demonstrated a lower risk for long-term weight gain
than the active comparators. Demonstrated differences in tolerability profiles among the different
choices of antipsychotics make it possible to attempt to match up an individual patient to the
best choice for such patient based on past history of tolerability, comorbidities, and personal
preferences, potentially improving adherence.
Keywords: antipsychotic, lurasidone, relapse, tolerability, schizophrenia, weight gain
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dopamine D2 and serotonin 5-HT2A receptors.9 Lurasidone’s
pharmacokinetic profile permits once-daily dosing, and
administration needs to be with food; it is recommended that
lurasidone be taken once daily in the evening, with a meal or
within 30 minutes after eating.9 Metabolism is primarily via
CYP3A4 and, consequently, its use is contraindicated in the
presence of strong inhibitors or inducers of CYP3A4 such as
ketoconazole or rifampin, respectively.9 Lurasidone appears
associated with minimal effects on body weight and low risk
for clinically meaningful alterations in glucose, lipids, or
electrocardiogram parameters.9
This review examines the lurasidone data regarding
relapse prevention in persons with schizophrenia, specifically
appraising the results from double-blind controlled trials.

Methods
A literature search was conducted on June 14, 2016, using
the following terms “lurasidone AND relapse” using the US
National Library of Medicine PubMed.gov resource. A total
of 22 records were found, of which three were primary
reports of double-blind randomized trials,10–12 and one was an
economic evaluation13 of one of the studies reported.11 One
of the studies was a classic randomized withdrawal placebocontrolled relapse prevention study,12 whereas the other two
studies compared lurasidone with quetiapine extended-release
(XR)11 and risperidone.10 These reports,10–12 together with any
study results posted on the ClinicalTrials.gov registry, were
the principal information sources for this review.

Results
Table 1 provides an overview of the three relevant studies:
Citrome et al,10 Loebel et al,11 and Tandon et al.12 Doses of
lurasidone tested were in the range of 40–160 mg/d.

NCT00641745
The first published randomized double-blind study of lurasidone that included relapse as an outcome measure was
a 12-month safety and tolerability study where 629 persons, aged between 18 and 75 years, with clinically stable
schizophrenia or schizoaffective disorder, were allocated to
receive flexibly dosed lurasidone 40–120 mg/d (n=427) or
risperidone 2–6 mg/d (n=202).10 The study was conducted
at 68 study centers located primarily in the United States
(40 sites; approximately two-thirds of all participants), but
also recruited patients in Argentina, Brazil, Chile, Croatia,
Israel, South Africa, and Thailand. Inclusion criteria included
the following: duration of illness 1 year; in a nonacute
phase of illness for 8 weeks; no change in antipsychotic
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medications, other than minor dose adjustments for
tolerability purposes, for 6 weeks before screening; no
hospitalization for psychiatric illness for 8 weeks; and
moderate or less severity rating on the Positive and Negative
Syndrome Scale (PANSS) items of delusions, conceptual
disorganization, hallucinations, and unusual thought content.
Among the exclusion criteria were treatment with risperidone
within 6 weeks before baseline, or a history of a poor or an
inadequate response, or intolerability to risperidone. Patients
who had been treated with a stable dose of antidepressants
or mood stabilizers for 1 month before the baseline visit
were allowed to continue this treatment during the study;
otherwise, subjects were not permitted to begin treatment
with these agents after the screening visit. Although the
primary outcome measure was the number of participants
with adverse events, efficacy outcomes included relapse rate,
PANSS total score, and the Clinical Global ImpressionsSeverity (CGI-S) score. Relapse was defined as worsening of
the PANSS total score by 30% from baseline and CGI-S 3;
rehospitalization for worsening of psychosis; or emergence
of suicidal ideation, homicidal ideation, and/or risk of harm
to self or others.

Relapse
A small proportion of subjects in the study experienced
a relapse (114/608, 19%). The rate of relapse among
lurasidone-treated patients was 20% (82/410), and that for
risperidone-treated patients, 16% (32/198), yielding a number
needed to treat (NNT) value of 27 (not statistically significant
[ns]) in favor of risperidone (for a brief overview of NNT,
see Box 1). For both treatment groups, the Kaplan–Meier
estimates of the probability of relapse were less than 0.5
at month 12; therefore, the median survival time to relapse
could not be calculated for either treatment group. The relapse
hazard ratio comparing lurasidone vs risperidone was 1.31
(95% confidence interval [CI]: 0.87–1.97; P=0.194). Because
the study was powered to test the noninferiority of lurasidone relative to risperidone on the basis of the assumption
of expected relapse rates of 35% for both treatment groups
after 1 year, the noninferiority test was uninterpretable
because the actual relapse rates were substantially lower
than initially predicted.

Other efficacy outcomes
The PANSS total score decreased from baseline to month 12
in both the lurasidone group (-4.7; 95% CI: -6.4 to -3.0) and
the risperidone group -6.5; 95% CI: -8.8 to -4.3), with no
significant differences between lurasidone and risperidone
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12 months

12 months

28 weeks

Citrome et al,10
NCT00641745

Loebel et al,11
NCT00789698

Tandon et al,12
NCT01435928

Total 285; lurasidone
144; placebo 141

Total 292; lurasidone
151; quetiapine XR 85;
lurasidone (on placebo
in parent study) 56

Total 629; lurasidone
427; risperidone 202

N randomized

Upon recruitment to the study, patients entered a transition
phase 7 days where antipsychotic medication was
discontinued. Patients who continued to fulfill the study
entry criteria were randomized (baseline) in a 2:1 ratio to
receive, starting on study day 1, either lurasidone 80 mg/d or
risperidone 2 mg/d. Lurasidone was to be dosed at 80 mg/d
on days 1–7, after which the dose could be adjusted to
between 40 and 120 mg/d. Risperidone was to be dosed at
2 mg/d on days 1 and 2 and then increased to 4 mg/d on
day 3. Beginning with day 8, risperidone dosing could be
adjusted to between 2 and 6 mg/d. The overall modal daily
dose was 80 mg for lurasidone (60% of the participants) and
4 mg for risperidone (62% of the participants).
Of the 353 subjects who completed the initial 6-week
double-blind parent trial, 292 (83%) entered the 12-month
relapse prevention study where lurasidone was started
at 120 mg/d for 7 days and quetiapine XR was continued
at 600 mg/d for 7 days;b dosing was flexible from then on
(lurasidone 40–160 mg/d, quetiapine XR 200–800 mg/d).
Of the patients receiving lurasidone, 58% received a modal
daily dose of 120 mg, and 28% received a modal daily dose
of 160 mg. Of the patients receiving quetiapine XR, 56%
received a modal daily dose of 600 mg, and 32% received a
modal daily dose of 800 mg.
Of the 676 subjects enrolled in the 12–24 week open-label
stabilization phase, 285 (42%) entered the double-blind phase.
Lurasidone dosing was flexible in the range of 40–80 mg/d.
During the open-label phase, the mean lurasidone dose was
68 mg/d and the modal daily dose was 80 mg in 73% of the
participants. During the double-blind phase, the mean daily
dose of lurasidone was 79 mg/d and the modal daily dose was
80 mg in 78.5% of the participants.

Study flow and dosing

0.66 (0.45–0.98)

0.73 (0.41–1.30)

1.31 (0.87–1.97)

Kaplan–Meier
analysis: relapse HR vs
comparator (95% CI)

Notes: aA negative NNT is interpreted as a disadvantage for lurasidone. bThis information on dose titration was included in a poster presentation.45
Abbreviations: CI, confidence interval; HR, hazard ratio; NNT, number needed to treat; ns, not statistically significant; XR, extended-release; N, number.

Length

Study and
ClinicalTrials.gov
registry number

Table 1 Double-blind randomized studies of lurasidone examining relapse in persons with schizophrenia

30% vs 41%

21% vs 27%

20% vs 16%

Observed relapse
rates (lurasidone
vs comparator)
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9 (5–426)

18 (ns)

-27 (ns)a

NNT vs
comparator
(95% CI)
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Box 1 What is NNT?
An NNT is a measure of effect size that is clinically intuitive. NNT answers the question: “How many patients would you need to treat with
Intervention A instead of Intervention B before you would expect to encounter one additional positive outcome of interest?” For the outcome
of avoidance of relapse, an NNT of “x” for a test medication vs placebo would mean you would have to treat “x” number of patients with the
test medication instead of with placebo before expecting to avoid one additional relapse. The lower the NNT, the more robust the intervention
is when compared to the alternative. NNT is a different concept than P-value, which relates to “statistical” significance. NNT is a measure of
“clinical” significance. A P-value, even as low as P0.00001, does not necessarily mean that a result is clinically relevant. To determine possible
clinical relevance (ie, clinical significance) effect size, such as NNT, needs to be evaluated.
NNT is simple to calculate:
A = frequency of outcome for Intervention A
B = frequency of outcome for Intervention B
NNT =1/(A–B), rounded up to a whole number
For example, if giving a test medication results in relapse of 25% over a 12-month period and giving placebo results in relapse of 50% over a 12month period, NNT for avoidance of relapse for the test medication vs placebo is 1/(50%–25%)=1/(0.50–0.25)=1/(0.25)=4. Thus, for every four
persons given the test medication instead of placebo, you would expect to avoid one additional relapse event.
A rule of thumb is that NNT values vs placebo 10 denote potentially useful interventions. Most psychotropic medications for most indications
have NNT values between 3 and 9 for clinically relevant definitions of response or efficacy. The lower the NNT, the more often desired
outcomes are encountered.
An additional tutorial for the use of NNT can be found at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140623/ and guidance on interpretation
is further available at http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12142/full. Both of these resources are free to access.
Abbreviation: NNT, number needed to treat.

in the PANSS total scores at any time during the 12-month
double-blind treatment period. Similarly, the CGI-S score
decreased from baseline to month 12 similarly in both the
lurasidone group (-0.4; 95% CI: -0.5 to -0.3) and the risperidone group (-0.4; 95% CI: -0.5 to -0.2).

Tolerability outcomes
The three most frequent adverse events among the lurasidonetreated patients (vs risperidone) were nausea (17% vs 11%),
insomnia (16% vs 13%), and sedation (15% vs 14%); the
three most frequent adverse events in the risperidone-treated
patients (vs lurasidone) were increased weight (20% vs 9%),
somnolence (18% vs 14%), and headache (15% vs 10%).
The rates of akathisia reported by patients as an adverse
event were 14% and 8% in the lurasidone and the risperidone groups, respectively; rates of discontinuation because
of akathisia were low in both groups (1.0% of lurasidone
patients and 1.5% of risperidone patients). Risperidone
was more likely to result in body weight gain of 7%, as
observed in 14% of subjects receiving risperidone vs 7% for
lurasidone-treated patients. Endpoint change in prolactin was
also higher with the risperidone group. All-cause discontinuation rates were higher for lurasidone vs risperidone: 269/419
(64%) for lurasidone and 105/202 (52%) for risperidone
in the safety population, resulting in an NNT of 9 (95%
CI: 5–26) in favor of risperidone. However, there were no
significant treatment differences for the time to discontinuation because of insufficient clinical response, an adverse
event, or withdrawal of consent.
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NCT00789698
A second long-term study that contrasted lurasidone with
an active comparator was a 12-month double-blind extension11 to a 6-week placebo-controlled acute treatment trial.14
Enrolled were 292 persons with schizophrenia, aged between
18 and 75 years, who received either flexibly dosed lurasidone 40–160 mg/d (n=207) or quetiapine XR 200–800 mg/d
(n=85).11 The study was conducted at 58 centers in six
countries, with approximately one-quarter of all participants
being from the United States. The primary relapse prevention
analysis population was defined as all subjects who were
randomized to either once-daily fixed doses of lurasidone
(80 or 160 mg) or quetiapine XR 600 mg in the initial 6 week
acute treatment study and who met clinical response criteria
at the end of that study. Response was defined as 20%
reduction in PANSS total score from acute study baseline
and a CGI-S 4. A total of 139 subjects receiving lurasidone
and 79 subjects receiving quetiapine XR were included in
the primary noninferiority analysis for relapse prevention.
Relapse was defined as worsening of 30% in the PANSS
total score from day 42 of the initial acute treatment study and
a CGI-S 3; rehospitalization for worsening of psychosis;
or emergence of suicidal ideation, homicidal ideation, and/
or risk of harm.

Relapse
The rate of relapse among lurasidone-treated patients was
21% (29/139), and that for quetiapine-treated patients, 27%
(21/79), yielding a number NNT of 18 (not statistically
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significant) in favor of lurasidone. For both treatment groups,
the Kaplan–Meier estimates of the probability of relapse were
less than 0.5 at month 12; therefore, the median survival
time to relapse could not be calculated for either treatment
group. The relapse hazard ratio comparing lurasidone vs
quetiapine was 0.73 (95% CI: 0.41–1.30), demonstrating
noninferiority.

Other efficacy outcomes
An advantage was found for lurasidone regarding hospitalization risk. The Kaplan–Meier estimate of the probability
of hospitalization at 12 months was significantly lower
for lurasidone vs quetiapine XR, at 10% vs 23% (NNT 8;
95% CI: 5–37; P0.05), resulting in a hazard ratio of 0.43
(95% CI: 0.19–1.0). More patients on lurasidone achieved
remission, as defined by Andreasen et al,15 compared to
patients receiving quetiapine XR with rates of 62% vs 46%,
respectively, resulting in an NNT of 7 (95% CI: 4–52). There
was significantly greater change in the PANSS total score
from the 12-month study baseline for lurasidone-treated
patients than for patients treated with quetiapine XR (-5.0
vs +1.7); however, changes in CGI-S scores were similar.

Tolerability outcomes
The three most frequent adverse events in the lurasidonetreated group were akathisia (13%), headache (11%), and
insomnia (8%); the three most frequent adverse events in
the quetiapine XR group were worsening of schizophrenia
(15%), insomnia (9%), and headache (9%). The rates of
akathisia reported by patients as an adverse event were 11%
and 2% in the lurasidone and the quetiapine XR groups,
respectively (and 13% among those initially on placebo
in the parent study and then switched to lurasidone in the
12-month study). Quetiapine XR was more likely to result in
weight gain of 7%, with this outcome observed in 27.5%
of subjects receiving quetiapine XR vs 14% for lurasidonetreated patients at 6 months, and 15% vs 11.5% at 12 months,
respectively, for observed cases. Rates of discontinuation due
to adverse events were similar: 7% for lurasidone-treated
patients and 5% for patients receiving quetiapine XR.

Other publications
Additional publications identified in PubMed.gov by searching on the ClinicalTrials.gov identifier NCT00789698 have
reported on improved cognitive performance in patients
treated with lurasidone compared to quetiapine XR.16,17
An economic impact study has also been published, demonstrating cost savings with lurasidone over quetiapine, driven

Patient Preference and Adherence 2016:10
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by the lower relapse-related hospitalization rates observed
with lurasidone.13

NCT01435928
A classic randomized withdrawal study has been published
where 285 persons with schizophrenia, aged 18–75 years,
met protocol-specified stabilization criteria and were randomized to receive lurasidone 40–80 mg/d (n=144) or placebo
(n=141) for up to 28 weeks.12 The study was conducted at
71 sites in seven countries, with 45 of the study sites located
in the United States and comprising approximately 70% of all
participants. Subjects were initially enrolled in an open-label
stabilization phase where 676 acutely ill patients received
12–24 weeks of treatment with lurasidone at a starting dose
of 40 mg/d, with flexible dosing permitted after 3 days up
until the last 4 weeks of the stabilization period, during
which no dose adjustments were permitted. Treatment with
antidepressant medications or mood stabilizers was allowed
in patients who had been taking a stable dose for 30 days
prior to the open-label stabilization phase baseline; however,
initiation or increase in dosage of these medications during
the study was prohibited. The protocol-specified stabilization criteria were that subjects maintained clinical stability
for 12 weeks during the open-label stabilization phase
and had remained on a stable dose of lurasidone for 4 weeks
prior to randomization. Clinical stability was defined as a
PANSS total score 70, with PANSS item scores 4 on
all positive subscale items and the general psychopathology
item for uncooperativeness, and a CGI-S score 4. There
was some flexibility to retain subjects if they had temporary
increases in their total PANSS score (up to 80), CGI-S of 4,
or a PANSS positive item of 5; two such events were allowed
after initial attainment of the stability criteria, except during the last 4 weeks of the open-label stabilization phase.
Once randomized, lurasidone dose was the same as the final
open-label dose but adjustments within the range of lurasidone 40–80 mg/d were subsequently allowed. Relapse was
defined as an increase of 25% from double-blind baseline
in PANSS total score and CGI-S worsening of 1 point for
two consecutive visits no more than 10 days apart; at any
single visit, a PANSS item score of 5 (moderately severe)
on hostility or uncooperativeness, or a PANSS item score
of 5 on two or more items of unusual thought content, delusions, conceptual disorganization, or hallucinatory behavior;
initiation of supplemental treatment with an antipsychotic
medication other than lurasidone, an increased dose of an
antidepressant or mood stabilizer, an increase in lorazepam
(or benzodiazepine equivalent) dose by 2 mg/d for at least
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3 days, or electroconvulsive therapy; insufficient clinical
response or exacerbation of underlying disease reported as
an adverse event, as determined by the study investigator;
deliberate self-injury or repeated aggressive behavior, active
suicidal or homicidal ideation or attempt; or psychiatric
hospitalization due to worsening schizophrenia.

Relapse
The rate of relapse among lurasidone-treated patients was
30% (43/144), and that for placebo-treated patients, 41%
(58/141), yielding an NNT of 9 (95% CI: 5–426) in favor of
lurasidone. The Kaplan–Meier estimates of the probability of
relapse at week 28 were 42% for patients receiving lurasidone
and 51% for the placebo group, with a median survival time
to relapse of about 28 weeks for subjects receiving placebo,
and it was not calculable for patients randomized to continue
treatment with lurasidone. The relapse hazard ratio comparing lurasidone vs placebo was 0.66 (95% CI: 0.45–0.98),
demonstrating superiority.

Other efficacy outcomes
Patients in the placebo-treated group evidenced worsening in
PANSS total and CGI-S scores compared to patients receiving lurasidone. Of note, differences in efficacy outcomes were
noted when comparing US with non-US sites; lurasidone
significantly delayed time to relapse in the non-US subgroup
(n=85, log-rank test, P=0.010) but not in the US subgroup
(n=200, log-rank test, P=0.414).

Tolerability outcomes
In the open-label stabilization phase, the most common
adverse events were akathisia (14%), headache (11%), and
nausea (10%). In the double-blind phase, the three most
frequent adverse events in the lurasidone-treated group were
schizophrenia (8%), insomnia (6%), and anxiety or back
pain (4% each); the three most frequent adverse events in
the placebo group were schizophrenia (9%), insomnia (7%),
and headache (3.5%). Rates of akathisia in the double-blind
phase were 2.1% for subjects receiving lurasidone and
2.8% for those receiving placebo. The discontinuation rate
due to adverse events (including the adverse event-related
relapse criterion of worsening of schizophrenia) during
the double-blind phase was 14% for lurasidone and 16%
for placebo. Minimal changes in weight, lipids, glucose,
and prolactin were observed. Moreover, in the patients
treated with lurasidone, mean weight change was -0.6 kg
as observed across the open-label and randomized phases,
with weight gain 7% and weight loss 7% experienced by
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a similar proportion of patients (17.4% and 16.7%, respectively). All-cause discontinuation rates were 48% and 58%,
for lurasidone- and placebo-treated subjects, respectively,
resulting in an NNT of 10 (ns), with a Kaplan–Meier probability of all-cause discontinuation at the week 28 endpoint
of 58% for the lurasidone group vs 70% for placebo (log
rank test, P=0.070).

Discussion
The efficacy of lurasidone for the maintenance treatment of patients with schizophrenia was tested in three
multicenter, randomized, controlled trials,10–12 including
a placebo-controlled, randomized withdrawal study. 12
Superiority to placebo and noninferiority to quetiapine
XR has been evidenced, with an uninterpretable relapse
outcome when lurasidone was compared with risperidone.
Doses tested span the range of that available for lurasidone,
40–160 mg/d; however, the placebo-controlled trial was
limited to 80 mg/d.12 This is somewhat problematic as it is
apparent that some patients may require higher doses in the
face of inadequate response to 80 mg/d.18,19 This limitation
in lurasidone dose in the placebo-controlled randomized
withdrawal study, together with possible study-conduct
problems at US sites (given the lack of signal detection
in the United States vs outside the United States), may
have led to the observed effect size that is less robust (and
less precise) than reported for other similar studies with
other second-generation antipsychotics (Table 2),20–28 and
as noted in a meta-analysis of placebo-controlled studies
of antipsychotic agents for relapse prevention in patients
with schizophrenia, which found from data published from
1962 to 2010, across 24 randomized trials, that treatments
reduced relapse rates at around 1 year (7–12 months) from
64% (placebo) to 27% (risk ratio: 0.40; 95% CI: 0.33–0.49;
risk difference: -39%; 95% CI: -46 to -32), for an NNT of
3.29,30 Figure 1 depicts the NNT vs placebo and 95% CIs for
the outcome of relapse (or impending relapse) from data
that have been published (or recently presented) of pivotal
placebo-controlled randomized withdrawal studies of the oral
first-line second-generation antipsychotics (there is no available study for quetiapine immediate-release or risperidone).
Indirect comparison reveals a degree of overlap for the 95%
CIs among the agents, including lurasidone vs aripiprazole,
brexpiprazole, cariprazine, olanzapine, paliperidone, and
ziprasidone. Although there is no overlap in the 95% CIs
for lurasidone vs quetiapine XR, this indirect comparison is
difficult to interpret, particularly in the face of noninferiority
for probability of relapse that was observed when lurasidone
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Antipsychotic

Length of doubleblind period

Lurasidone12
Aripiprazole20
Asenapine21
Brexpiprazole22
Cariprazine23
Iloperidone24
Olanzapine25
Paliperidone26
Quetiapine IR
Quetiapine XR27
Risperidone
Ziprasidone28

Up to 28 weeks
285
0.66 (0.45–0.98)
Up to 26 weeks
310
0.50 (0.35–0.71)
Up to 26 weeks
386
Not reported
Up to 52 weeks
202
0.29 (CI not reported)
Up to 72 weeks
200
0.45 (0.28–0.73)
Up to 26 weeks
195
0.21 (0.12–0.37)
Up to 52 weeks
326
6 month: 0.10 (0.05–0.22)
Variable; no set limit
207
Not reported
No relevant registration studies available
Up to 52 weeks
197
Interim: 0.16 (0.08–0.34)
No relevant placebo-controlled registration studies available
Up to 52 weeks
294
Not reported

N randomized

Kaplan–Meier analysis: relapse
HR vs placebo (95% CI)

Observed relapse
rates vs placebo

NNT vs placebo
(95% CI)

30% vs 41%
34% vs 57%
12% vs 47%
13.5% vs 38.5%
25% vs 47.5%
16.5% vs 54.2%a
4% vs 37%
22% vs 51.5%

9 (5–426)
5 (3–9)
3 (3–4)
4 (3–8)
5 (3–11)
3 (2–4)
3 (3–5)
4 (3–6)

12% vs 48.5%

3 (3–4)

34.5% vs 61%

4 (3–8)

Notes: aPersonal Communication, Mallery Mayo, Vanda Pharmaceuticals Inc., July 13, 2016. The observed relapse rates were not reported in the published paper.
Abbreviations: CI, confidence interval; HR, hazard ratio; NNT, number needed to treat; IR, immediate release; XR, extended-release; N, number.

was directly compared with quetiapine XR.11 An important
caveat is that randomized withdrawal studies can differ
substantially in terms of open-label stabilization periods
(if any), stabilization criteria, length of observation, and
relapse criteria. The efficacy profile for each alternative also
needs to be considered within the context of tolerability and
safety.8 For example, as observed in the relapse-prevention
studies of lurasidone, although lurasidone was associated
with generally higher rates of akathisia, quetiapine XR and
risperidone were more likely to result in weight gain.

The maintenance of a therapeutic response with longterm use of lurasidone for schizophrenia is also supported
by several open-label extension studies of up to 22 months in
duration.31–33 The long-term effect of lurasidone 40–160 mg/d
on body weight after 12 months of treatment in persons
with schizophrenia was examined in a pooled analysis
of 593 observed cases;34 subjects were participants from
the two 12-month randomized studies reviewed here,10,11
combined with data from a 22-month open-label extension
study,31 a 12-month extension study (NCT00088621), a
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Table 2 Placebo-controlled randomized withdrawal studies of first-line oral second-generation antipsychotics in persons with
schizophrenia

Figure 1 NNT vs placebo and 95% CIs for the outcome of relapse (or impending relapse) from available data from the pivotal placebo-controlled randomized withdrawal
studies of the oral first-line second-generation antipsychotics (there is no available study for quetiapine immediate-release or risperidone).
Abbreviations: NNT, number needed to treat; XR, extended-release; CI, confidence interval.
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Japanese 44-week open-label extension of a 8-week doubleblind study, and a Japanese 12-month open-label study that
enrolled acute patients. Mean baseline weight was 72.8,
80.8, and 72.4 kg in the lurasidone (n=471), risperidone
(n=89), and quetiapine XR (n=33) groups, respectively. At
the end of 1 year, mean weight change was -0.4 kg with
lurasidone, +2.6 kg with risperidone, and +1.2 kg with quetiapine XR. Weight gain 7% was seen in 16%, 26%, and
15% of patients, while weight loss 7% was observed in
18.5%, 7%, and 9%, respectively. Lurasidone thus appears
to have a lower risk for long-term weight gain than some
other second-generation antipsychotics, and these data are
consistent with that observed in short-term acute clinical
trials for both schizophrenia35 and bipolar depression36 and
in the 24-week open-label extension study for bipolar depression.37 Body weight is easily monitored during routine office
visits, and avoiding overweight and obesity is an important
strategy in managing risk for metabolic syndrome, diabetes,
and cardiovascular disease.38 Patients with weight gain may
be less likely to be adherent to their prescribed medications
as observed in a nationwide survey of 876 US adults with
schizophrenia and taking antipsychotic medication, where
about 26% reported bothersome weight gain.39
Studies examining quality-of-life improvements among
persons with schizophrenia treated with lurasidone have
been published.40,41 In a 24-week extension32 of an open-label
6-week switch study,42 health-related quality of life was measured using the self-reported Personal Evaluation of Transitions in Treatment scale and Short-Form 12 questionnaire;
improvements were observed on both of these measures,
including components assessing adherence-related attitude
and psychosocial functioning.41
No singular medication is perfect for everyone.8 Additional
choices for antipsychotics for the treatment of schizophrenia
are also desirable to accommodate the wide range of preexisting tolerability issues that patients may have.43 Consideration
should also be given to other formulations, such as longacting injectables, particularly in the maintenance phase of
treatment, assuming the suitability of the currently available
options for the individual person being treated.44
In summary, the overall available data support the use of
lurasidone for relapse prevention. Long-term safety and tolerability mirrors that observed during short-term acute trials,
with advantages in terms of a more favorable weight gain
profile than many other available choices,6,7 and consequently
a lower risk for problematic alterations in lipid profile and
the development of insulin resistance.
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